United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

Posted by Geri Gentry on Sep 18th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $497.54, for a total transaction of $4,129,582.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $22,474,876.88. The trade was a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Price Performance

United Therapeutics stock traded down $2.64 during trading hours on Friday, hitting $494.63. The company had a trading volume of 1,473,643 shares, compared to its average volume of 513,087. The firm has a market cap of $21.21 billion, a PE ratio of 17.70, a PEG ratio of 2.50 and a beta of 0.56. United Therapeutics Corporation has a one year low of $408.75 and a one year high of $609.35. The firm has a 50-day moving average of $516.53 and a 200 day moving average of $540.64.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the company posted $6.41 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. As a group, research analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Arjuna Capital lifted its holdings in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares during the period. Sage Rhino Capital LLC boosted its position in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC increased its stake in United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. raised its position in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares in the last quarter. Finally, Kera Capital Partners Inc. raised its position in United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 27 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Royal Bank Of Canada reduced their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00.

Check Out Our Latest Stock Analysis on United Therapeutics

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.